nach oben

vorheriger Artikel Advanced basal cell carcinoma

nächster Artikel Merkelzellkarzinom: eine Überprüfung und Aktual...

Tipp

Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach

Zeitschrift:: Wiener Medizinische Wochenschrift > Ausgabe 15-16/2013

Autoren:: MD Michael Tronnier, MD, PhD Kristina Semkova, MD Uwe Wollina, MD Georgi Tchernev

Summary

In faired skinned population the incidence of melanoma is rapidly increasing. Beside environmental factors (UV-exposure) certainly other reasons for the observed “melanoma epidemic” have to be discussed. For diagnostic procedure classical histopathology is accompanied by immunohistochemistry and more recently molecular techniques. For therapy new modalities are available which—after many years of frustrating search for new drugs—are now able to prolong both disease/progression free and overall survival.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Erickson C, Driscoll MS. Melanoma epidemic: facts and controversies. Clin Dermatol. 2010;28:281–5. PubMedCrossRef

Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666–74. PubMedCrossRef

Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3–9. PubMedCrossRef

Volkovova K, Bilanicova D, Bartonova A, et al. Associations between environmental factors and incidence of cutaneous melanoma. Rev. Environ Health. 2012;11:1–12. CrossRef

Erdmann F, Lortet-Tieulent J, Schüz J, et al. International trends in the incidence of malignant melanoma. 1953–2008—are recent generations at higher or lower risk? Int J Cancer. 2012;132:385–400. PubMedCrossRef

Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systemic review of epidemiologic studies. Cancer Causes Control. 2001;12:69–82. PubMedCrossRef

Weyers W. The “epidemic” of melanoma between under- and overdiagnosis. J Cutan Pathol. 2012;29:9–16. CrossRef

Choudhury K, Volkmer B, Greinert R, et al. Effectiveness of skin cancer screening programs. Br J Dermatol. 2012;167:94–8. PubMedCrossRef

Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives? Cancer. 2012;118:5395–402. PubMedCrossRef

10.

Andersen LK, Hercogová J, Wollina U, et al. Climate change and skin disease: a review of the English-language literature. Int J Dermatol. 2012;51:656–61. PubMedCrossRef

11.

Zalaudek I, Docimo G, Argenziano G. Using dermatosopic criteria and patient-related factors for the management of pigmented melanocytic nevi. Arch Dermatol. 2009;145:816–26. PubMedCrossRef

12.

Wollina U, Burroni M, Torricelli R, et al. Digital dermoscopy in clinical practice: a three-center analysis. Skin Res Technol. 2007;13:133–42. PubMedCrossRef

13.

Herman C. Emerging technologies for the detection of melanoma: achieving better outcomes. Clin Cosmet Investig Dermatol. 2012;5:195–212. PubMedCrossRef

14.

Ackerman AB, Cerroni L, Kerl H. Pitfalls in the histopathologic diagnosis of malignant melanoma. Philadelphia: Lea & Febiger; 1994.

15.

Tronnier M. Einflussfaktoren auf die Mikromorphologie von melanozytären Naevi. JDDG. 2004;2:987–9. PubMedCrossRef

16.

Cerroni L, Kerl H. Tutorial on melanocytic lesions. Am J Dermatopathol. 2001;23:237–41. PubMedCrossRef

17.

Cerroni L, Barnhill R, Elder D, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol. 2010;34:314–26. PubMedCrossRef

18.

Gerami P, Scolger RA, Xu X, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol. 2013;37(5):676–84. PubMedCrossRef

19.

Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther. 2006;19:40–9. PubMedCrossRef

20.

Pflugfelder A, Weide B, Eigentler TK, et al. Incisional biopsy and melanoma prognosis: facts and controversies. Clin Dermatol. 2010;28:316–8. PubMedCrossRef

21.

Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—update 2012. Eur J Cancer. 2012;48:2375–90. PubMedCrossRef

22.

Iorizzo LJ 3rd, Chocron I, Lumbang W, et al. Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in-situ. Dermatol Surg. 2013;39:365–71. PubMedCrossRef

23.

Beger J, Hansel G, Krönert C, et al. A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. Int J Dermatol. 2013;52:220–30. PubMedCrossRef

24.

Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J. 2012;18:192–202. PubMedCrossRef

25.

Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet. 2008;372:117–26. PubMedCrossRef

26.

Powell AM, Robson AM, Russell-Jones R, et al. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol. 2009;160:994–8. PubMedCrossRef

27.

Hervieu A, Rébé C, Végran F, et al. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol. 2013;133:499–508. PubMedCrossRef

28.

Daponte A, Signoriello S, Maiorino L, et al. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-Α in advanced malignant melanoma. J Transl Med. 2013;13:11–38.

29.

Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14. PubMedCrossRef

30.

Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012;6:391–405. PubMed

31.

Salama AK, Kim KB. Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013;14:619–27. PubMedCrossRef

32.

Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703. PubMedCrossRef

33.

Hanaizi Z, van Zwieten-Boot B, Calvo G, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Hum. Eur J Cancer. 2012;48:237–42. PubMedCrossRef

34.

Hersh EM, O’Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011;29:489–98. PubMedCrossRef

Titel: Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach
Autoren:: MD Michael Tronnier
MD, PhD Kristina Semkova
MD Uwe Wollina
MD Georgi Tchernev
Publikationsdatum: 01.08.2013
DOI: https://doi.org/10.1007/s10354-013-0207-3
Verlag: Springer Vienna
Zeitschrift: Wiener Medizinische Wochenschrift
Ausgabe 15-16/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2013

Nachruf Prof. Dr. Walter H. Hörl 11.7.1945 – 25.6.2013

Skin cancer treatment options: new horizons and promises for the future

Advanced basal cell carcinoma

Cutaneous side effects of vemurafenib: a case report and discussion

Merkelzellkarzinom: eine Überprüfung und Aktualisierung über die Pathogenese, Diagnose und Therapieansätze

Atypical fibroxanthoma—a diagnosis of exclusion!